172 related articles for article (PubMed ID: 36124781)
1. An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Song AB; Al-Samkari H
Expert Rev Hematol; 2022 Oct; 15(10):875-885. PubMed ID: 36124781
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
3. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
4. Updates and advances in pyruvate kinase deficiency.
Luke N; Hillier K; Al-Samkari H; Grace RF
Trends Mol Med; 2023 May; 29(5):406-418. PubMed ID: 36935283
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
Grace RF
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):97-106. PubMed ID: 38066940
[TBL] [Abstract][Full Text] [Related]
6. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
Zhuang-Yan A; Shirley M
Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
[TBL] [Abstract][Full Text] [Related]
7. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
8. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
[TBL] [Abstract][Full Text] [Related]
9. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
10. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
11. The variable manifestations of disease in pyruvate kinase deficiency and their management.
Al-Samkari H; Van Beers EJ; Kuo KHM; Barcellini W; Bianchi P; Glenthøj A; Del Mar Mañú Pereira M; Van Wijk R; Glader B; Grace RF
Haematologica; 2020 Sep; 105(9):2229-2239. PubMed ID: 33054048
[TBL] [Abstract][Full Text] [Related]
12. Management of pyruvate kinase deficiency in children and adults.
Grace RF; Barcellini W
Blood; 2020 Sep; 136(11):1241-1249. PubMed ID: 32702739
[TBL] [Abstract][Full Text] [Related]
13. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
14. Pyruvate kinase deficiency in children.
Chonat S; Eber SW; Holzhauer S; Kollmar N; Morton DH; Glader B; Neufeld EJ; Yaish HM; Rothman JA; Sharma M; Ravindranath Y; Wang H; Breakey VR; Sheth S; Bradeen HA; Al-Sayegh H; London WB; Grace RF
Pediatr Blood Cancer; 2021 Sep; 68(9):e29148. PubMed ID: 34125488
[TBL] [Abstract][Full Text] [Related]
15. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.
Grace RF; Bianchi P; van Beers EJ; Eber SW; Glader B; Yaish HM; Despotovic JM; Rothman JA; Sharma M; McNaull MM; Fermo E; Lezon-Geyda K; Morton DH; Neufeld EJ; Chonat S; Kollmar N; Knoll CM; Kuo K; Kwiatkowski JL; Pospíšilová D; Pastore YD; Thompson AA; Newburger PE; Ravindranath Y; Wang WC; Wlodarski MW; Wang H; Holzhauer S; Breakey VR; Kunz J; Sheth S; Rose MJ; Bradeen HA; Neu N; Guo D; Al-Sayegh H; London WB; Gallagher PG; Zanella A; Barcellini W
Blood; 2018 May; 131(20):2183-2192. PubMed ID: 29549173
[TBL] [Abstract][Full Text] [Related]
16. How we manage patients with pyruvate kinase deficiency.
Grace RF; Mark Layton D; Barcellini W
Br J Haematol; 2019 Mar; 184(5):721-734. PubMed ID: 30681718
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate Kinase Deficiency: Current Challenges and Future Prospects.
Fattizzo B; Cavallaro F; Marcello APML; Vercellati C; Barcellini W
J Blood Med; 2022; 13():461-471. PubMed ID: 36072510
[TBL] [Abstract][Full Text] [Related]
18. Identification and in silico characterization of a novel PKLR genotype in a Turkish newborn.
Canu G; De Paolis E; Righino B; Mazzuccato G; De Paolis G; Capoluongo E; De Rosa MC; Urbani A; Gunes AM; Minucci A
Mol Biol Rep; 2020 Oct; 47(10):8311-8315. PubMed ID: 32974842
[TBL] [Abstract][Full Text] [Related]
19. A New Variant of PKLR Gene Associated With Mild Hemolysis may be Responsible for the Misdiagnosis in Pyruvate Kinase Deficiency.
Aydin Köker S; Oymak Y; Bianchi P; Gözmen S; Karapinar TH; Fermo E; Vergin RC
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e1-e2. PubMed ID: 30028822
[TBL] [Abstract][Full Text] [Related]
20. Alu element insertion in PKLR gene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients.
Lesmana H; Dyer L; Li X; Denton J; Griffiths J; Chonat S; Seu KG; Heeney MM; Zhang K; Hopkin RJ; Kalfa TA
Hum Mutat; 2018 Mar; 39(3):389-393. PubMed ID: 29288557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
